Celecoxib, a COX-2 inhibitor, reveals anticancer activity in CRC, breast cancer, prostate cancer, and head and neck cancer.1278 A phase IV trial of celecoxib as adjuvant therapy to chemotherapy in subjects with metastasis CRC (NCT03645187) is ongoing. The gene discussed is PTGS2; the disease is colorectal carcinoma.